These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17724372)

  • 21. The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer.
    Daragó A; Sapota A; Matych J; Nasiadek M; Skrzypińska-Gawrysiak M; Kilanowicz A
    Clin Chem Lab Med; 2011 Oct; 49(10):1699-705. PubMed ID: 21671822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
    Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of nutrients on insulin-like growth factor-I, insulin-like growth factor binding protein-3 and their ratio in African American and white males.
    McGreevy KM; Hoel BD; Lipsitz SR; Hoel DG
    Public Health Nutr; 2007 Jan; 10(1):97-105. PubMed ID: 17212848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of polymorphisms in genes encoding for insulin-like growth factor (IGF)-I, insulin, and IGF-binding protein (IGFBP)-3 on IGF-I, IGF-II, and IGFBP-3 levels in umbilical cord plasma.
    Landmann E; Kollerits B; Kreuder JG; Blum WF; Kronenberg F; Rudloff S
    Horm Res Paediatr; 2012; 77(6):341-50. PubMed ID: 22739332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States).
    Li L; Yu H; Schumacher F; Casey G; Witte JS
    Cancer Causes Control; 2003 Oct; 14(8):721-6. PubMed ID: 14674736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort.
    DeLellis K; Rinaldi S; Kaaks RJ; Kolonel LN; Henderson B; Le Marchand L
    Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1444-51. PubMed ID: 15342444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
    Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP
    Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men.
    Park K; Kim JH; Jeon HG; Byun SS; Lee E
    Urology; 2010 Jun; 75(6):1516.e1-7. PubMed ID: 20350746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.
    Allen NE; Key TJ; Appleby PN; Travis RC; Roddam AW; Rinaldi S; Egevad L; Rohrmann S; Linseisen J; Pischon T; Boeing H; Johnsen NF; Tjønneland A; Grønbaek H; Overvad K; Kiemeney L; Bueno-de-Mesquita HB; Bingham S; Khaw KT; Tumino R; Berrino F; Mattiello A; Sacerdote C; Palli D; Quirós JR; Ardanaz E; Navarro C; Larrañaga N; Gonzalez C; Sanchez MJ; Trichopoulou A; Travezea C; Trichopoulos D; Jenab M; Ferrari P; Riboli E; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1121-7. PubMed ID: 17548673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk.
    Jernström H; Chu W; Vesprini D; Tao Y; Majeed N; Deal C; Pollak M; Narod SA
    Mol Genet Metab; 2001 Feb; 72(2):144-54. PubMed ID: 11161840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.
    Chokkalingam AP; McGlynn KA; Gao YT; Pollak M; Deng J; Sesterhenn IA; Mostofi FK; Fraumeni JF; Hsing AW
    Cancer Res; 2001 Jun; 61(11):4333-6. PubMed ID: 11389055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
    Sarma AV; Dunn RL; Lange LA; Ray A; Wang Y; Lange EM; Cooney KA
    Prostate; 2008 Feb; 68(3):296-305. PubMed ID: 18163429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom.
    Young NJ; Metcalfe C; Gunnell D; Rowlands MA; Lane JA; Gilbert R; Avery KN; Davis M; Neal DE; Hamdy FC; Donovan J; Martin RM; Holly JM
    Cancer Causes Control; 2012 Jun; 23(6):907-17. PubMed ID: 22527168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IGF gene polymorphisms and breast cancer in African-American and Hispanic women.
    Sarkissyan M; Mishra DK; Wu Y; Shang X; Sarkissyan S; Vadgama JV
    Int J Oncol; 2011 Jun; 38(6):1663-73. PubMed ID: 21455574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.
    Mikami K; Ozasa K; Nakao M; Miki T; Hayashi K; Watanabe Y; Mori M; Sakauchi F; Washio M; Kubo T; Suzuki K; Wakai K; Nakachi K; Tajima K; Ito Y; Inaba Y; Tamakoshi A;
    Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():57-61. PubMed ID: 20553083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J; Diamandi A; Mistry J; Scorilas A
    J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort.
    Cheng I; Penney KL; Stram DO; Le Marchand L; Giorgi E; Haiman CA; Kolonel LN; Pike M; Hirschhorn J; Henderson BE; Freedman ML
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1993-7. PubMed ID: 17035411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y; Sakai H; Hayashi T; Kanetake H
    Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.